ANGO

$10.71

Post-MarketAs of Mar 17, 8:00 PM UTC

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$10.71
Potential Upside
5%
Whystock Fair Value$11.25
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internation...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$441.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-15.26%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.20

Recent News

Zacks
Mar 11, 2026

Reasons to Add AngioDynamics Stock to Your Portfolio for Now

ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 10, 2026

AngioDynamics CEO Details Portfolio Shift as Auryon, AlphaVac and NanoKnife Fuel Growth at Conference

AngioDynamics (NASDAQ:ANGO) CEO Jim Clemmer said the company has spent the last several years reshaping its portfolio and operating model, moving away from slower-growth, more commodity-oriented markets and toward what he described as larger, faster-growing med-tech categories where outcomes can be

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 27, 2026

Bastion Bets on Government Spending with $8 Million New Stake in Parsons

Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 25, 2026

TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates

TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 13, 2026

DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth

DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.